Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announ...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a le...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
Gain Therapeutics, a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapi...
-DoseMe, a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Au...
FibroBiologics, , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...
Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in pat...
Invisalign® Palatal Expanders offer doctors an effective and easily removable alternative to traditional palatal expanders, without the need for meta...
Telix Pharmaceuticals Limited (ASX: TLX) has announced a strategic agreement to partner with ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaf...
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the Europea...
Biocon Biologics Ltd (BBL), a leading biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), has announced a significant five-ye...
© 2024 Biopharma Boardroom. All Rights Reserved.
